EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative Renal Outcomes and Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation: Insights from Real-World Data

Karatpetch Tongkate iD, Thoranis Chantrarat iD, Pornwalai Boonmuang iD, Weerayuth Saelim iD, Narisa Ruenroengbun iD, Junporn Kongwatcharapong iD

Medicina · 13.03.2026 · 62 (3) · 532

DOI: 10.3390/medicina62030532 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Medicina, online erschienen am 13.03.2026. Verfasst von Karatpetch Tongkate und 5 weiteren Autor:innen. Beteiligte Einrichtung: The College of Pharmacotherapy of Thailand, Nonthaburi 11000, Thailand. Hauptthemen laut MEDLINE: Atrial Fibrillation, Warfarin, Anticoagulants. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Doctor Kasem Pangsrivongse Foundation, Eastern Asia University, Doctor Kasem Pangsrivongse Foundation, Thailand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: While non-vitamin K antagonist oral anticoagulants (NOACs) show better renal preservation than warfarin in nonvalvular atrial fibrillation (NVAF) patients, real-world evidence within Asian populations remains limited. This study compared the renal outcomes between NOACs and warfarin in Thai patients with NVAF. Materials and Methods: A retrospective cohort study was conducted among NVAF patients who received either NOACs or warfarin from two university hospitals in Thailand from January 2015 to December 2019. The primary outcome was a ≥30% decline in the estimated glomerular filtration rate (eGFR) with a doubling of the serum creatinine (SCr), while acute kidney injury (AKI) and incidence rate of stroke and systemic embolism event (SEE) were secondary outcomes. All outcomes of each NOAC versus the warfarin group were analyzed using Cox proportional hazards regression.

Results

A total of 1456 patients were enrolled. During a follow-up period of 24 months, NOACs were associated with a lower risk of a ≥30% decline in the eGFR than warfarin after inverse probability of treatment weighting (IPTW) and multivariable adjustment (adjusted hazard ratio (aHR) of 0.67, 95% confidence interval [CI] 0.45–1.00, p = 0.050). No significant differences were observed between NOACs and warfarin regarding the doubling of SCr (aHR 0.64, 95% CI 0.24–1.72, p = 0.373) or AKI (aHR 0.69, 95% CI 0.41–1.17, p = 0.169), although a trend toward a lower risk was noted in the NOAC group. Similarly, a trend toward a lower risk of the incidence rate of ischemic stroke and SEE were observed in the NOAC group (aHR 0.49, 95% CI 0.22–1.10, p = 0.084).

Conclusions

In real-world data, NOACs may be associated with a lower eGFR decline and lower doubling of SCr and AKI than warfarin. Additionally, NOACs may reduce the risk of ischemic stroke and SEE, supporting their potential benefit over warfarin in both renal and thromboembolic outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationWarfarinAnticoagulantsHumansMaleFemaleRetrospective StudiesAgedGlomerular Filtration RateAdministration, OralThailandAged, 80 and overMiddle AgedStrokeProportional Hazards ModelsAcute Kidney InjuryCohort StudiesTreatment Outcome

Stichwörter der Autor:innen

atrial fibrillationnon-vitamin K antagonistrenal outcomeswarfarin

Substanzen

WarfarinAnticoagulants

Autor:innen und Institutionen

  • The College of Pharmacotherapy of Thailand, Nonthaburi 11000, Thailand.
  • Pharmaceutical Care Division, School of Pharmacy, Eastern Asia University, Pathum Thani 12110, Thailand.
  • Division of Cardiology, Department of Medicine, Phramongkutklao Hospital, Bangkok 10400, Thailand.
  • Division of Pharmaceutical Care, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom 73000, Thailand.
  • Pharmacy Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.

ORCID-Profile: Karatpetch Tongkate, Thoranis Chantrarat, Pornwalai Boonmuang, Weerayuth Saelim, Narisa Ruenroengbun, Junporn Kongwatcharapong

Förderung

  • Doctor Kasem Pangsrivongse Foundation
  • Eastern Asia University
  • Doctor Kasem Pangsrivongse Foundation, Thailand
  • Eastern Asia University, Thailand

Zitieren

APA

Tongkate, K., Chantrarat, T., Boonmuang, P., Saelim, W., Ruenroengbun, N., & Kongwatcharapong, J. (2026). Comparative Renal Outcomes and Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation: Insights from Real-World Data. Medicina, 62(3), 532. https://doi.org/10.3390/medicina62030532

Vancouver

Tongkate K, Chantrarat T, Boonmuang P, Saelim W, Ruenroengbun N, Kongwatcharapong J. Comparative Renal Outcomes and Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation: Insights from Real-World Data. Medicina. 2026;62(3):532. doi:10.3390/medicina62030532

BibTeX
@article{Tongkate2026,
  author = {Tongkate, Karatpetch and Chantrarat, Thoranis and Boonmuang, Pornwalai and Saelim, Weerayuth and Ruenroengbun, Narisa and Kongwatcharapong, Junporn},
  title = {Comparative Renal Outcomes and Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation: Insights from Real-World Data},
  journal = {Medicina},
  year = {2026},
  volume = {62},
  number = {3},
  pages = {532},
  doi = {10.3390/medicina62030532}
}
Kostenlos starten →